Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Open-label Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of IMT504 Phosphorothioate Oligonucleotide, an Immunomodulator and Tissue Repair Inducer, in Healthy Volunteers

NCT06312423 is registered in ClinicalTrials.gov with Ministry of Public Health of the Province of La Rioja as lead sponsor.

NCT NCT06312423
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06312423 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Open-label Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of IMT504 Phosphorothioate Oligonucleotide, an Immunomodulator and Tissue Repair Inducer, in Healthy Volunteers
Lead sponsor
Ministry of Public Health of the Province of La Rioja
Phase
Phase 1
Overall status
Unknown status
Start date
February 23, 2024
Completion date
December 30, 2024
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

immune system